Admitting Orders for HIV-Positive Pregnant Patient with Suppressed Viral Load for Normal Spontaneous Delivery
For an HIV-positive pregnant patient with suppressed viral load (<1000 copies/mL) admitted for normal spontaneous delivery, continue her current combination antiretroviral therapy (cART) on schedule throughout labor and delivery, administer intravenous zidovudine (ZDV) as continuous infusion during labor (2 mg/kg loading dose over 1 hour, then 1 mg/kg/hr until delivery), and plan for the infant to receive 6 weeks of oral zidovudine starting within 6-12 hours of birth. 1, 2
Maternal Intrapartum Management
Antiretroviral Therapy During Labor
- Continue all current cART medications on their regular schedule throughout labor and delivery to maintain viral suppression and minimize resistance development 2
- Start IV zidovudine infusion when labor begins or upon admission:
- Loading dose: 2 mg/kg IV over 1 hour
- Maintenance: 1 mg/kg/hr continuous infusion until cord clamping 1
Mode of Delivery
- Vaginal delivery is appropriate for patients with viral load <1000 copies/mL at or near delivery 3, 4
- The transmission risk is 1-2% or lower with sustained viral suppression, independent of delivery route 3, 4
Intrapartum Precautions
- Minimize duration of ruptured membranes when possible 2
- Avoid invasive monitoring: no fetal scalp electrodes 2, 5
- Avoid operative vaginal delivery: no forceps or vacuum extraction 2
Neonatal Orders
Infant Antiretroviral Prophylaxis
- Zidovudine syrup for 6 weeks, starting within 6-12 hours of birth 1
- Coordinate with pediatrics/neonatology for dosing and administration
Additional Admitting Orders
Laboratory
- Consider obtaining viral load on admission if most recent result is >2-4 weeks old, though this is institution-dependent 6
- The 2007 guidelines predate routine admission viral load testing, but recent practice patterns show this is increasingly common 6
Postpartum Planning
- Evaluate need for continued antiretroviral therapy after delivery 1
- If cART was initiated solely for prevention of mother-to-child transmission and patient does not meet criteria for treatment of her own HIV disease, discuss discontinuation options
- Special consideration for NNRTI-containing regimens: If regimen includes drugs with long half-lives (e.g., nevirapine, efavirenz), consider stopping NRTIs 3-7 days after stopping the NNRTI to prevent resistance, though data are limited 1
Infant Follow-up
- Arrange HIV testing for the infant using virologic assays (HIV DNA or RNA PCR) per CDC/AAP guidelines, as antibody tests will be positive due to maternal antibody transfer 7
Important Clinical Caveats
The evidence strongly supports vaginal delivery for virally suppressed patients. The older guidelines [1-2] recommended cesarean delivery for viral loads ≥1000 copies/mL, but with viral loads <1000 copies/mL, cesarean delivery offers minimal additional benefit while increasing maternal morbidity (infection risk, surgical complications) 2.
Do not stop antiretroviral medications during labor. Maintaining therapeutic drug levels throughout delivery is critical for preventing transmission and avoiding resistance development 2.
The zidovudine infusion is given in addition to, not instead of, the patient's current cART regimen. This represents the intrapartum component of the three-part PACTG 076 protocol that remains standard of care 1, 2.